Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: neovasc.com
Number of Employees: 60
Year Founded: 2000
Total Amount Raised (CAD mm)†: 125.09
Total Rounds of Funding**:15
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada. Neovasc Inc. operates as a subsidiary of Shockwave Medical, Inc.

Financial Information (Currency: CAD, in mm) 
Total Revenue
5.2
Market Capitalization
113.5
TEV/Total Revenue
18.4x
EBITDA
(51.9)
Total Enterprise Value
96.2
TEV/EBITDA
NM
EBIT
(52.0)
Cash & ST Invst.
35.4
P/Diluted EPS Before Extra
NM
Net Income
(56.6)
Total Debt
17.9
Price/Tang BV
5.2x
Capital Expenditure
(0.1)
Total Assets
53.2
Total Debt/EBITDA
NM
U.S. Number of Employees 2023
-
U.S. Number of Employees 2022
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Dec-31-2022 TEV and Market Cap are calculated using a close price as of Apr-10-2023

Key Professionals
Name
Title
Colen, Fredericus A.
President, CEO & Director
Clark, Christopher 
CFO & Corporate Secretary
Milne, Susan 
Vice President of Human Resources
Panton, John Christopher
Chief Quality Officer

Key Board Members
Name
Title
Rubin, Steven D.
Independent Chairman of the Board
Colen, Fredericus A.
President, CEO & Director
Geyer, Paul L.
Independent Director
Janzen, Douglas Glen
Independent Director
Marko, Alexei J.
Independent Director
Radow, Norman J.
Independent Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
13700 Mayfield Place Suite 2135 | Richmond, BC | V6V 2E4 | Canada
Phone: 604-270-4344   Fax: 604-270-4384

Parent Company
Shockwave Medical, Inc. (NasdaqGS:SWAV)

Prior Investors
Advantage Growth Fund, B.C. Advantage (VCC) Funds Ltd., Boston Scientific Corporation (NYSE:BSX), Fidelity Investments, Frost Group, LLC, Gagnon Securities, LLC, Incentive Management Inc. (Lior Shahory), Incubator LP, Magnetar Capital Partners, LP, Northview LifeSciences (Douglas Janzen), OPKO Health, Inc. (NasdaqGS:OPK), Pender Growth Fund Inc. (TSXV:PTF), PenderFund Capital Management Ltd., Peregrine Investment Management, Inc., Peregrine VC Investments II LP, Peregrine Ventures (Boaz Lifschitz), Peregrine Ventures II, L.P., Saints Capital Services, LLC, Strul Medical Group LLC, The Advantage Venture Fund, L.P.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
B Balloon Ltd.
As of June 30, 2008, B Balloon, Ltd. was acquired by Neovasc, Inc. B Balloon, Ltd., a medical device company, engages in the research and development in the cardio vascular technologies for the interventional treatment of heart and vascular diseases. The company develops stents and stent delivery systems that allow the percutaneous placement of stents in coronary bifurcation and ostial lesions in coronary and peripheral arteries. B Balloon, Ltd. is based in Or Yehuda, Israel.

Africa / Middle East
Health Care Equipment
-
0.00
0.00
Neovasc Medical Ltd.
Neovasc Medical Ltd., a cardiovascular medical device company, develops a solution for patients who cannot benefit from bypass, PCIs, and other traditional revascularization techniques. It develops a minimally invasive procedure in which a stent inserted percutaneously into the coronary sinus partially restricts the flow of blood exiting into the arteries. The company was founded in 2002 and is based in Or Yehuda, Israel. As of June 30, 2008, Neovasc Medical Ltd. operates as a subsidiary of Neovasc Inc.

Africa / Middle East
Health Care Equipment
-
1.00
0.00
Angiometrx Inc.
As of May 2003, Angiometrx Inc. operates as a subsidiary of Neovasc Inc.

United States and Canada
-
-
-
-
PM Devices Inc.
PM Devices Inc. (PMD) manufactures, research, and sells medical devices for cardiovascular problems. The company’s products include PeriPatch, StepSaverCylinder, and Correstore Patch. Its products are for surgical purposes. The company is based in Richmond, Canada. As of 03/18/2002, PM Devices Inc. is a subsidiary of Medical Ventures Corp.

United States and Canada
Health Care Equipment
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-17-2023
Apr-11-2023
Merger/Acquisition
Target
Neovasc Inc.
Shockwave Medical, Inc. (NasdaqGS:SWAV)
Strul Medical Group LLC
143.10
Apr-22-2022
Apr-11-2023
Shelf Registration
Target
Neovasc Inc.

Strul Medical Group LLC
6.14
Mar-24-2022
Mar-24-2022
Private Placement
Target
Neovasc Inc.
Strul Medical Group LLC

10.37
Apr-16-2021
-
Shelf Registration
Target
Neovasc Inc.


150.00
Feb-10-2021
Feb-12-2021
Public Offering
Target
Neovasc Inc.


72.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Apr-12-2023
Delistings
Neovasc's Common Shares to Be Delisted from TSX, Nasdaq
Apr-11-2023
Index Constituent Drops
Neovasc Inc.(NasdaqCM:NVCN) dropped from NASDAQ Composite Index
Apr-11-2023
Shelf Registration Filings
Neovasc Inc. has closed its Shelf Registration dated April 22, 2022 in the amount of $6.142713 million.
Apr-11-2023
Shelf Registration Filings
Neovasc Inc. has withdrawn its Shelf Registration dated April 16, 2021 in the amount of $150 million.
Apr-11-2023
Shelf Registration Filings
Neovasc Inc. has closed its Shelf Registration dated June 05, 2018 in the amount of $7.440739 million.

Competitors
Edwards Lifesciences Corporation (NYSE:EW), LifeNet Health, Inc.

M&A Advisors
Blake, Cassels & Graydon LLP, Lang Michener LLP, Piper Sandler & Co., Skadden, Arps, Slate, Meagher & Flom LLP


Advisors
Most Recent Auditor
Grant Thornton International Ltd.
M&A Advisors
Blake, Cassels & Graydon LLP, Lang Michener LLP, Piper Sandler & Co., Skadden, Arps, Slate, Meagher & Flom LLP
Private Placement Advisors
Canaccord Genuity Corp., Cormark Securities Inc., Macquarie Capital Markets Canada Ltd., Macquarie Private Wealth Inc., Raymond James Ltd.
Public Offering Advisors
Blake, Cassels & Graydon LLP, Grant Thornton LLP, Grant Thornton LLP, H.C. Wainwright & Co., LLC, Skadden, Arps, Slate, Meagher & Flom LLP, Wilson Sonsini Goodrich & Rosati, P.C.


Most Recent Auditor
Grant Thornton


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 26, 2023 05:09 AM
Neovasc Inc.
Neovasc Inc (NVCN.NASD) - Medical Equipment - Deals and Alliances Profile
Reports
48
GlobalData

Sep 15, 2023 04:46 AM
Neovasc Inc.
Neovasc Inc (NVCN.TSE) - Medical Devices Product Pipeline Summary
Reports
141
MarketLine

Sep 14, 2023 06:01 AM
Neovasc Inc.
Neovasc Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
306
GlobalData

Sep 11, 2023 11:02 PM
Neovasc Inc.
Neovasc Inc (NVCN.TSE) - Financial Analysis Review
Reports
441
GlobalData

Jun 09, 2023 06:55 AM
Neovasc Inc.
Neovasc Inc (NVCN.TSE) - Medical Devices Product Pipeline Summary
Reports
140
GlobalData

Jun 09, 2023 03:19 AM
Neovasc Inc.
Neovasc Inc (NVCN.TSE) - Financial Analysis Review
Reports
441
GlobalData

May 09, 2023 03:51 AM
Neovasc Inc.
Neovasc Inc (NVCN.NASD) - Medical Equipment - Deals and Alliances Profile
Reports
48
H.C. Wainwright & Co.
Bernardino, Vernon Tolentino
Apr 14, 2023 02:35 PM
Neovasc Inc.
Acquisition by Shockwave Medical Closed; Dropping Coverage
Reports
4
CFRA Equity Research

Apr 13, 2023 03:05 AM
Neovasc Inc.
Neovasc Inc.
Reports
9
The Economy Matters

Apr 10, 2023 02:11 AM
Neovasc Inc.
The Economy Matters
Reports
8


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


CM-CIC Asset Management SA

27,540

-

0.8

Jun-30-2023


0778432 BC Ltd

0

-

0.0

Jun-30-2023


Janzen, Douglas Glen

0

-

0.0

Apr-11-2023


ProEquities, Inc., Asset Management Arm

0

-

0.0

Jun-30-2023


Morgan Stanley, Investment Banking and Brokerage Investments

0

-

0.0

Jun-30-2023


Marko, Alexei J.

0

-

0.0

Apr-11-2023


Sio Capital Management, LLC

0

-

0.0

Jun-30-2023


UBS Asset Management AG

0

-

0.0

Jun-30-2023


Rubin Esq., J.D., Steven D.

0

-

0.0

Jun-30-2023


CSS LLC/IL, Asset Management Arm

0

-

0.0

Jun-30-2023



No Data Available.



Top Buyers
Buyers
Common Stock Equivalent Held
Change
CM-CIC Asset Management SA
27,540
27,540
Blackstone Alternative Investment Advisors LLC
0
16

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Tudor Investment Corporation
0
(185,831)
Black Maple Capital Management LP
0
(107,685)
Janzen, Douglas Glen
0
(38,894)
Yakira Capital Management, Inc.
0
(37,425)
MM Asset Management Inc
0
(27,722)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Consulting Services, Contract Manufacturing Services, CorRestore Patch, Covered Stent, Neovasc Reducer, Over and Under Stent, Peripatch Surgical Patches, Tiara (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Apr-17-2023
Mar-30-2023
Neovasc Inc.
SEDAR
Annual Financial Statements
16 KB
Apr-12-2023
Apr-12-2023
Neovasc Inc.
SEC
6-K
34 KB
Apr-12-2023
-
Neovasc Inc.
SEDAR
Change in Corporate Structure
12 KB
Apr-12-2023
-
Neovasc Inc.
SEDAR
Material Change Report
14 KB
Apr-11-2023
-
Neovasc Inc.
SEDAR
Documents Affecting the Rights of Security Holders
170 KB
Apr-11-2023
-
Neovasc Inc.
SEDAR
Documents Affecting the Rights of Security Holders
1 MB
Apr-11-2023
-
Neovasc Inc.
SEDAR
Securities Acquisition Filings (Early Warning)
133 KB
Apr-11-2023
Apr-11-2023
Neovasc Inc.
SEC
6-K
4 MB
Apr-11-2023
-
Neovasc Inc.
SEC
RW
7 KB
Apr-11-2023
-
Neovasc Inc.
SEC
F-10POS
27 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Janzen, Douglas Glen (Independent Director)
Mar-17-2023
Common Shares
197
-
Derivative Exercise and Retained Stock
0.51
Multiple
Janzen, Douglas Glen (Independent Director)
Feb-21-2023
Common Shares
56
-
Derivative Exercise and Retained Stock
0.14
Multiple
Little, William Reed (Former Chief Operating Officer)
Dec-03-2022
Common Shares
1,249
0
Derivative Exercise and Retained Stock
18.67
Multiple
Little, William Reed (Former Chief Operating Officer)
Dec-03-2022
Common Shares
(789)
(9,484)
Derivative Exercise and Sale
-
Multiple
-
Dec-03-2022
Common Shares
789
0
Derivative Exercise
-
Exchange Announcement
-
Dec-03-2022
Common Shares
(789)
(9,484)
Sale
-
Exchange Announcement
Geyer B.A.Sc., P.Eng, P.Eng., Paul L. (Independent Director)
Nov-18-2022
Common Shares
3,000
26,788
Open Market Acquisition
19.54
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Rubin, Steven D.
Independent Chairman of the Board
604-270-4344
604-270-4384

Colen, Fredericus A.
President, CEO & Director
604-270-4344
604-270-4384

Geyer, Paul L.
Independent Director
604-270-4344
604-270-4384

Janzen, Douglas Glen
Independent Director
604-428-4641
604-270-4384

Marko, Alexei J.
Independent Director
604-270-4344
604-270-4384

Radow, Norman J.
Independent Director
604-270-4344
604-270-4384
norman@radco.us
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Colen, Fredericus A.
President, CEO & Director
604-270-4344
604-270-4384

Clark, Christopher 
CFO & Corporate Secretary
(604) 248-4138
604-270-4384
cclark@neovasc.com
Milne, Susan 
Vice President of Human Resources
604-270-4344
604-270-4384
smilne@neovasc.com
Panton, John Christopher
Chief Quality Officer
604-270-4344
604-270-4384

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
